Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Visual Adaptation and Quality of Life After Different IOL Implantation Strategies

NCT07740590 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-03-01
Last updated
2026-07-31

Condition(s) studied

CataractAphakia - Lens Capsule Present

Investigational drug(s) / intervention(s)

Bilateral Bifocal IOL ImplantationBifocal and EDOF IOL Mix-and-Match ImplantationBifocal and Monofocal IOL Mix-and-Match Implantation

Bilateral Bifocal IOL Implantation: Bilateral phacoemulsification with bifocal intraocular lens implantation in both eyes.

Bifocal and EDOF IOL Mix-and-Match Implantation: Bilateral phacoemulsification with bifocal intraocular lens implantation in one eye and EDOF intraocular lens implantation in the contralateral eye.

Bifocal and Monofocal IOL Mix-and-Match Implantation: Bilateral phacoemulsification with bifocal intraocular lens implantation in one eye and monofocal intraocular lens implantation in the contralateral eye.

Study summary

This longitudinal observational study aims to evaluate long-term visual adaptation trajectories, optical quality, and patient-reported outcomes in age-related cataract patients following bilateral implantation of multifocal or mix-and-match intraocular lenses (IOLs). Patients will be followed up longitudinally after surgery to systematically assess visual performance and quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older with age-related cataract requiring bilateral phacoemulsification and intraocular lens (IOL) implantation * Corneal astigmatism less than 0.75 D * Good general health and willing to complete all postoperative follow-up visits * Signed written informed consent Exclusion Criteria: * Previous ocular surgery or ocular trauma * Coexisting ocular diseases affecting visual potential, such as corneal opacity, glaucoma, macular degeneration, or diabetic retinopathy * Intraoperative or postoperative complications (e.g., posterior capsule rupture) * Systemic diseases that may interfere with visual outcomes or follow-up compliance

Primary outcome measure(s)

  • Subjective Visual Adaptation Score (Multifocal Motor Adaptation Questionnaire, MMAQ) — Preoperatively, and postoperatively at 1 week, 1 month, 3 months, and 6 months
    Assessed using the Multifocal Motor Adaptation Questionnaire (MMAQ), a custom-designed questionnaire developed by the research team to measure subjective visual adaptation and symptoms in patients following intraocular lens implantation. Scores range from 0 to 100, with higher scores indicating higher levels of visual adaptation and satisfaction.

Trial sites (1)

FacilityCityRegionStatus
Sichuan Provincial People's Hospital Chengdu China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07740590 on ClinicalTrials.gov ↗ ← All trials in China